Clinical Trials Logo

Clinical Trial Summary

Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies. This trial aims to tell the distribution of IPA origin in Chinese patients.


Clinical Trial Description

Infrapyloric artery(IPA) is of great importance for gastric cancer patients. In early gastric cancer patients, the pylorus-preserving gastrectomy requires the preserving of IPA. In advanced gastric cancer patients, the subgroup of No. 6 lymph node might be associated with IPA. In Japanese Gastric Cancer Association(JGCA) gastric cancer classification guidelines, the No. 6 lymph nodes is defined as lymph nodes along the first branch and proximal part of the right gastroepiploic artery(RGEA) down to the confluence of the right gastroepiploic vein and the anterior superior pancreatoduodenal vein. However,if IPA origins from the gastroduodenal artery(GDA) or anterior superior pancreatoduodenal artery(ASPDA), the lymph nodes along the IPA can not be grouped into the No. 6 lymph nodes. Thus, a new definition of No. 6 lymph nodes is needed on the basis of the origin of IPA.

Previous studies about IPA origin are few and the origin of IPA varies greatly among different studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03071237
Study type Observational
Source Peking University
Contact
Status Completed
Phase
Start date March 4, 2017
Completion date December 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT05645198 - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy Phase 4
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00290966 - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Not yet recruiting NCT06085677 - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Recruiting NCT02969122 - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor N/A
Completed NCT01482299 - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression Phase 2
Active, not recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Completed NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Recruiting NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Phase 2
Completed NCT05714878 - Multimodal Prehabilitation for Resectable Gastric Cancer N/A
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05640609 - Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer Phase 1/Phase 2